Eli Lilly has invested $40 million in Absci, a generative AI drug discovery company, as part of a larger $100 million stock offering. Absci utilized AI to design ABS-201, an injectable antibody targeting a hormone receptor implicated in hair growth and reproductive health, intended for treating pattern baldness and endometriosis. This investment highlights a growing trend of pharmaceutical giants backing AI-driven drug development, with the potential for combined therapies like hair regrowth and weight loss. AI
IMPACT Accelerates the trend of AI-driven drug discovery and potential for novel combined therapies.
RANK_REASON Significant investment in an AI drug discovery company by a major pharmaceutical firm. [lever_c_demoted from significant: ic=1 ai=0.7]
- Alphabet
- Earendil Labs
- Eli Lilly
- Isomorphic Labs
- Pfizer
- Ransi Somaratne
- Sanofi
- Sean McClain
- Mounjaro
- Xaira Therapeutics
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
